Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Abhay Sharma

Hospitalist Canfield, OH Medical Doctor

NPI 1124469408 CMS profile 2787727

7171 Paddington Rowe, Canfield, OH 44406

Open in the dashboard

General payments

$1,088

60 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Abhay Sharma of Canfield, OH is reported in the CMS Open Payments database as having received $1,088 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20 1
2024 General $144 3
2023 General $268 12
2022 General $251 16
2021 General $186 13
2020 General $72 4
2019 General $147 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abhay Sharma
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Abhay Sharma were reported at $20. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Abhay Sharma Hospitalist median Middle half National median
2019 $147 $96 $28–$201 $163
2020 $72 $48 $19–$125 $114
2021 $186 $70 $23–$167 $132
2022 $251 $85 $27–$174 $149
2023 $268 $89 $30–$191 $160
2024 $144 $95 $29–$204 $164
2025 $20 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $192 9 payments
  2. AbbVie, Inc. $148 5 payments
  3. Lilly USA, LLC $139 10 payments
  4. Merck Sharp & Dohme Corporation $66 5 payments
  5. AstraZeneca Pharmaceuticals LP $57 4 payments
  6. DePuy Synthes Sales Inc. $53 1 payment
  7. Axsome Therapeutics, Inc. $51 2 payments
  8. Biohaven Pharmaceuticals, Inc. $50 3 payments
  9. Mylan Pharmaceuticals Inc. $48 3 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $39 2 payments
  11. Other $245 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,067 59 payments
  2. Debt forgiveness $21 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $94 6 payments
  2. AREXVY $68 1 payment
  3. JARDIANCE $58 4 payments
  4. CRANIOPLASTIC $53 1 payment
  5. Auvelity $51 2 payments
  6. NURTEC ODT $50 3 payments
  7. Xulane $48 3 payments
  8. BELSOMRA $42 3 payments
  9. STEGLATRO $42 3 payments
  10. TRULICITY $39 3 payments
  11. Other $659 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

406

Median for Internal Medicine: 777

Drug cost

$48,735

Median for Internal Medicine: $73,373

Branded share of claims

21.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 17 $23,163
Nuedexta Dextromethorphan Hbr/Quinidine Brand 26 $19,828
Rivastigmine Rivastigmine Tartrate Brand 14 $1,173
Levetiracetam Generic 13 $666
Baclofen Generic 13 $536
Omeprazole Generic 35 $446
Atorvastatin Calcium Generic 39 $418
Gabapentin Generic 25 $364
Metformin Hcl Generic 44 $360
Lisinopril-Hydrochlorothiazide Lisinopril/Hydrochlorothiazide Brand 16 $332

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$41,614

Medicare's payments for the services billed

Medicare patients

335

Average age 76

Services billed

359

189 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 70%
Diabetes 53%
Chronic kidney disease 52%
Depression 46%
Heart failure 45%
Ischemic heart disease 44%
COPD 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record